CDH13 silencing creates a fivefold increase in risk.
Oregon Health & Science University Cancer Institute researchers report that silencing the gene CDH13 is predictive of prostate cancer recurrence.
While this gene is active tn normal cells, in some cancer cells, it may be turned off, which leads to a propensity for metastasis, according to the OHSU team.
In the study, the researchers looked at tissue samples from 151 subjects with localized prostate cancer with at least five years of follow-up after their prostatectomies. They observed that two-third of the subjects were free of recurrence.
The investigators found that men whose tumors showed a silencing of CDH13 had a fivefold increased risk of prostate cancer recurrence compared to men whose tumors showed no silencing of this gene.
The research will be presented at the “2008 American Society of Clinical Oncology Genitourinary Symposium.”